NCT02717156: Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors |
|
|
| Recruiting | 2 | 170 | US | Computed Tomography, CAT, CAT Scan, Computerized Axial Tomography, Computerized Tomography, CT, CT SCAN, tomography, Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET SCAN, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, Recombinant EphB4-HSA Fusion Protein, sEphB4-HSA | University of Southern California, National Cancer Institute (NCI) | Stage IV Bladder Urothelial Carcinoma, Prostate Cancer, Urothelial Carcinoma | 11/25 | 11/26 | | |
| Active, not recruiting | 1 | 63 | Europe, US | AN0025, E7046, Pembrolizumab, KEYTRUDA®, MK-3475-879 | Adlai Nortye Biopharma Co., Ltd., Merck Sharp & Dohme LLC | Triple-negative Breast Cancer, NSCLC, Squamous or Non-Squamous, Urothelial Carcinoma of the Bladder, Microsatellite Stable (MSS) Colorectal Cancer (CRC), Cervical Cancer | 05/24 | 01/25 | | |
